Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 4: Once-weekly IcoSema vs once-daily insulin glargine in type 2 diabetes
CTR20240303Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of icosema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2024; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20240303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240303.